FOR IMMEDIATE RELEASE
CONTACT: Tracy Morris
650-473-1272
tracy@morrismarcom.com
ASSOCIATION FOR MOLECULAR PATHOLOGY 2006 ANNUAL MEETING:
EXPERTS TO PREVIEW MULTI-CENTER CLINICAL VALIDATION RESULTS
FOR PATHWORK DIAGNOSTICS' NOVEL ONCOLOGY DIAGNOSTICS SYSTEM
San Jose, Calif. --- Sept. 28, 2006 --- Helping to usher in a new era in molecular diagnostics for oncology, leading experts will preview results from Pathwork Diagnostics' multi-center clinical validation study for a novel microarray-based cancer system at a workshop at the Association for Molecular Pathology's (AMP) 2006 Annual Meeting to be held November 16-19 in Orlando, Fla. Renowned speakers will discuss preliminary results regarding Pathwork's Tissue of Origin (TOO) test, which may aid in the determination of the origin of metastatic cancers. Also included will be a challenging case study addressing clinical utility.
Who: |
Rick Klausner, M.D., Partner, The Column Group; former Director, National Cancer Institute |
|
When: |
Thursday, November 16, 3:00 p.m. - 4:00 p.m. EST |
|
Where: |
AMP 2006 Annual Meeting, Gaylord Palms Resort and Convention Center in Orlando, Fla., Tallahassee Room |
|
Contact: |
AMP2006@pathworkdx.com to register or for more information |
Background
Metastatic tumors of uncertain origin - where a presumptive diagnosis can be made, but the physician is unsure - are a common problem. Cancer of Unknown Primary (CUP), for example, represents the seventh to eighth most frequent type of cancer worldwide and the fourth most common cause of cancer death. The National Comprehensive Cancer Network's guidelines emphasize the importance of identifying the tissue of origin so that cancer-specific treatment recommendations can be followed. Current pathologic techniques, however, identify the primary tumor site only 25 percent of the time in living patients. Pathwork Diagnostics will have completed an extensive clinical validation study of their microarray-based assay addressing this unmet clinical need and will share the most recent results at the AMP meeting.
About Pathwork Diagnostics
Pathwork Diagnostics (Booth #315 at AMP 2006) develops innovative molecular diagnostic tests for cancer that are designed to provide pathologists and oncologists with high-value information that can help transform patient care. The company's tests combine proprietary genomic analytics on a microarray platform and are developed in collaboration with leading cancer centers and universities. Pathwork Diagnostics is located in San Jose, Calif. For more information, please visit www.pathworkdx.com or call 408-279-4390.